

Eosinophilic Esophagitis Toolkit

Resource	Address
Allakos announces topline phase 3 data from the ENIGMA 2 study and phase 2/3 data from the KRYPTOS study in patients with eosinophilic gastrointestinal diseases. December 21, 2021.	https://investor.allakos.com/news-releases/news-release-details/allakos-announces-topline-phase-3-data-enigma-2-study-and-phase
Capucilli P, Hill DA. Allergic comorbidity in eosinophilic esophagitis: Mechanistic relevance and clinical implications. <i>Clin Rev Allergy Immunol</i> . 2019;57(1):111-127. doi:10.1007/s12016-019-08733-0	https://pubmed.ncbi.nlm.nih.gov/30903437/
Collins MH, Martin LJ, Alexander ES, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. <i>Dis Esophagus</i> . 2017;30(3):1-8. doi:10.1111/dote.12470	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5373936/
Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). <i>Am J Gastroenterol</i> . 2013;108(5):679-693. doi:10.1038/ajg.2013.71	https://pubmed.ncbi.nlm.nih.gov/23567357/
Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. <i>Gastroenterology</i> . 2018;154(2):319-332.e3. doi:10.1053/j.gastro.2017.06.067	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794619/
Dellon ES, Katzka DA, Collins MH, et al. Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis. <i>Gastroenterology</i> . 2017;152(4):776-786.e5. doi:10.1053/j.gastro.2016.11.021	https://pubmed.ncbi.nlm.nih.gov/27889574/
Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: Proceedings of the AGREE Conference. <i>Gastroenterology</i> . 2018;155(4):1022-1033.e10. doi:10.1053/j.gastro.2018.07.009	https://pubmed.ncbi.nlm.nih.gov/30009819/
Dellon ES, Rothenberg ME, Collins MH, et al. LB3 - A phase 3, randomized, 3-part study to investigate the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic esophagitis: Results from part A. Presented at the 2020 ACG Annual Scientific Meeting. October 26, 2020.	https://eventscribe.com/2020/ACG/speakers.asp

<p>Dellon ES, Woosley JT, Arrington A, et al. Efficacy of budesonide vs fluticasone for initial treatment of eosinophilic esophagitis in a randomized controlled trial. <i>Gastroenterology</i>. 2019;157(1):65-73.e5. doi:10.1053/j.gastro.2019.03.014</p>	<p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581596/</p>
<p>Dellon ES. Management of refractory eosinophilic oesophagitis. <i>Nat Rev Gastroenterol Hepatol</i>. 2017;14(8):479-490. doi:10.1038/nrgastro.2017.56</p>	<p>https://pubmed.ncbi.nlm.nih.gov/28536485/</p>
<p>Dellon ES. Red between the lines: Evolution of eosinophilic esophagitis as a distinct clinicopathologic syndrome. <i>Dig Dis Sci</i>. 2020;65(12):3434-3447. doi:10.1007/s10620-020-06642-3</p>	<p>https://pubmed.ncbi.nlm.nih.gov/33052498/</p>
<p>Doerfler B, Bryce P, Hirano I, Gonsalves N. Practical approach to implementing dietary therapy in adults with eosinophilic esophagitis: The Chicago experience. <i>Dis Esophagus</i>. 2015;28(1):42-58. doi:10.1111/dote.12175</p>	<p>https://pubmed.ncbi.nlm.nih.gov/24602224/</p>
<p>FDA approves first treatment for eosinophilic esophagitis, a chronic immune disorder. May 20, 2022.</p>	<p>https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-eosinophilic-esophagitis-chronic-immune-disorder</p>
<p>Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: A systematic review and consensus recommendations for diagnosis and treatment. <i>Gastroenterology</i>. 2007;133(4):1342-1363. doi:10.1053/j.gastro.2007.08.017</p>	<p>https://pubmed.ncbi.nlm.nih.gov/17919504/</p>
<p>Gonsalves N, Yang GY, Doerfler B, Ritz S, Ditto AM, Hirano I. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. <i>Gastroenterology</i>. 2012;142(7):1451-1459.e1. doi:10.1053/j.gastro.2012.03.001</p>	<p>https://pubmed.ncbi.nlm.nih.gov/22391333/</p>
<p>Gonsalves N. Dietary therapy in eosinophilic esophagitis. <i>Gastrointest Endosc Clin N Am</i>. 2018;28(1):89-96. doi:10.1016/j.giec.2017.07.008</p>	<p>https://pubmed.ncbi.nlm.nih.gov/29129302/</p>
<p>Greuter T, Hirano I, Dellon ES. Emerging therapies for eosinophilic esophagitis. <i>J Allergy Clin Immunol</i>. 2020;145(1):38-45. doi:10.1016/j.jaci.2019.10.027</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31705907/</p>
<p>Hirano I, Aceves SS. Clinical implications and pathogenesis of esophageal remodeling in eosinophilic esophagitis. <i>Gastroenterol Clin North Am</i>. 2014;43(2):297-316. doi:10.1016/j.gtc.2014.02.015</p>	<p>https://pubmed.ncbi.nlm.nih.gov/24813517/</p>
<p>Hirano I, Chan ES, Rank MA, et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. <i>Gastroenterology</i>. 2020;158(6):1776-1786. doi:10.1053/j.gastro.2020.02.038</p>	<p>https://www.gastrojournal.org/article/S0016-5085(20)30265-1/fulltext</p>

<p>Hirano I, Chan ES, Rank MA, et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. <i>Ann Allergy Asthma Immunol.</i> 2020;124(5):416-423. doi:10.1016/j.anai.2020.03.020</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32336462/</p>
<p>Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. <i>Gastroenterology.</i> 2020;158(1):111-122.e10. doi:10.1053/j.gastro.2019.09.042</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31593702/</p>
<p>Hirano I, Furuta GT. Approaches and challenges to management of pediatric and adult patients with eosinophilic esophagitis. <i>Gastroenterology.</i> 2020;158(4):840-851. doi:10.1053/j.gastro.2019.09.052</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31836530/</p>
<p>Hirano I, Moy N, Heckman MG, Thomas CS, Gonsalves N, Achem SR. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: Validation of a novel classification and grading system. <i>Gut.</i> 2013;62(4):489-495. doi:10.1136/gutjnl-2011-301817</p>	<p>https://pubmed.ncbi.nlm.nih.gov/22619364/</p>
<p>Hirano I, Safroneeva E, Roumet MC, et al. Randomised clinical trial: The safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis. <i>Aliment Pharmacol Ther.</i> 2020;51(8):750-759. doi:10.1111/apt.15670</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32149424/</p>
<p>Hirano I. How I approach the management of eosinophilic esophagitis in adults. <i>Am J Gastroenterol.</i> 2017;112(2):197-199. doi:10.1038/ajg.2016.515</p>	<p>https://pubmed.ncbi.nlm.nih.gov/27845336/</p>
<p>Leigh LY, Spergel JM. An in-depth characterization of a large cohort of adult patients with eosinophilic esophagitis. <i>Ann Allergy Asthma Immunol.</i> 2019;122(1):65-72.e1. doi:10.1016/j.anai.2018.09.452</p>	<p>https://pubmed.ncbi.nlm.nih.gov/30223114/</p>
<p>Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: Updated consensus recommendations for children and adults. <i>J Allergy Clin Immunol.</i> 2011;128(1):3-20.e6. doi:10.1016/j.jaci.2011.02.040</p>	<p>https://pubmed.ncbi.nlm.nih.gov/21477849/</p>
<p>Lucendo AJ, Miehke S, Schlag C, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. <i>Gastroenterology.</i> 2019;157(1):74-86.e15. doi:10.1053/j.gastro.2019.03.025</p>	<p>https://pubmed.ncbi.nlm.nih.gov/30922997/</p>
<p>Moawad FJ, Dellon ES, Achem SR, et al. Effects of race and sex on features of eosinophilic esophagitis. <i>Clin Gastroenterol Hepatol.</i> 2016;14(1):23-30. doi:10.1016/j.cgh.2015.08.034</p>	<p>https://pubmed.ncbi.nlm.nih.gov/26343181/</p>

<p>Molina-Infante J, Lucendo AJ. Dietary therapy for eosinophilic esophagitis. <i>J Allergy Clin Immunol.</i> 2018;142(1):41-47. doi:10.1016/j.jaci.2018.02.028</p>	<p>https://pubmed.ncbi.nlm.nih.gov/29522850/</p>
<p>Rank MA, Sharaf RN, Furuta GT, et al. Technical review on the management of eosinophilic esophagitis: A report from the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters. <i>Ann Allergy Asthma Immunol.</i> 2020;124(5):424-440.e17. doi:10.1016/j.anai.2020.03.021</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32336463/</p>
<p>Rank MA, Sharaf RN, Furuta GT, et al. Technical review on the management of eosinophilic esophagitis: A report from the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters. <i>Gastroenterology.</i> 2020;158(6):1789-1810.e15. doi:10.1053/j.gastro.2020.02.039</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32359563/</p>
<p>Rothenberg M, Dellon E, Bradenoord A, et al. Dupilumab improves clinical and histologic aspects of disease in adult and adolescent patients with eosinophilic esophagitis at week 24: Results from part B of the 3-part LIBERTY EoE TREET study. <i>J Allergy Clin Immunol.</i> 2022;149(2 suppl):AB312. doi:10.1016/j.jaci.2021.12.003</p>	<p>https://www.jacionline.org/article/S0091-6749(21)01826-1/fulltext</p>
<p>Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. <i>Gastroenterology.</i> 2013;145(6):1230-1236.e62. doi:10.1053/j.gastro.2013.08.015</p>	<p>https://pubmed.ncbi.nlm.nih.gov/23954315/</p>
<p>Spergel JM, Brown-Whitehorn TF, Cianferoni A, et al. Identification of causative foods in children with eosinophilic esophagitis treated with an elimination diet. <i>J Allergy Clin Immunol.</i> 2012;130(2):461-467.e5. doi:10.1016/j.jaci.2012.05.021</p>	<p>https://pubmed.ncbi.nlm.nih.gov/22743304/</p>
<p>Takeda receives Complete Response Letter from the U.S. FDA for TAK-721. December 21, 2021.</p>	<p>https://www.takeda.com/en-us/newsroom/news-releases/2021/takeda-receives-complete-response-letter-from-the-us-fda-for-tak-721/</p>